Agape ATP Corporation (ATPC) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Agape ATP Corp (ATPC) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, Agape ATP is a tiny Malaysia-based healthcare company that looks more like a high-risk survival-and-repositioning story than a stable operating business right now. > **📍 Basic Profile** > > Market Cap **$3.2 million** · Health Care · NASDAQ NMS - GLOBAL MARKET · Price **$3.20** > **⚡ 3 Things You Should Know** > > 1. ⚠️ **Very weak earnings base:** Gross margin is decent at 52.7%, but net margin is a shocking **-182.6%**, which basically means the core issue is not product economics alone—it’s that the company’s cost structure and scale are nowhere near healthy yet. > > 2. 📉 **This is a micro-cap with listing-risk history:** ATPC recently went through a **1-for-50 reverse split**, received Nasdaq delisting/noncompliance notices, and then regained compliance. In other words, the stock is still tradable, but this recent history tells you survival on the exchange has been part of the story. > > 3. 🎯 **The market is trading hope, not proof:** The stock jumped sharply in the latest session and the company announced a UAE collaboration tied to oil, gas, and commodities opportunities, but the financials don’t yet show a profitable turnaround—so this is more of a speculation on future deals than confidence in current fundamentals. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin -182.59%, ROE -15.01% | > | Growth Rate | Steady📈 | Revenue growth 3Y CAGR 9.05%, but 5Y CAGR -3.12% | > | Financial Health | Healthy💚 | Debt/equity 7.09%, current ratio 16.21 | > | Valuation | [Data unavailable] | PE unavailable; PS 2.16x, PB 2.44x | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** [Data unavailable] — based on the classification, it is a healthcare company, but the provided data does not include a detailed segment breakdown; recent announcements suggest it is also exploring business through a green energy subsidiary and cross-sector partnerships. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Healthcare operations | [Data unavailable] | [Data unavailable] | Core business details were not provided | | Other / strategic initiatives | [Data unavailable] | ↑ | Recent news points to expansion efforts beyond traditional healthcare | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 52.68% | Above Average | Product-level margin looks workable, which is interesting | | Net Margin | -182.59% | Below Average | The company is losing far more than it earns in revenue—major red flag | | ROE | -15.01% | Average | Negative returns on shareholder capital show weak business efficiency | --- #### 📈 How's the Growth? **Growth Assessment:** Slowing | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | 3Y CAGR 9.05% | [Data unavailable] | Mixed | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > What’s worth noting is that the growth picture is messy. The 3-year revenue growth is positive, but the 5-year figure is negative, which usually means the company has not built a clean, consistent expansion story. Basically, this does not look like smooth organic compounding—it looks more uneven and fragile. --- #### 💰 Financial Health Check **One Sentence:** Think of it like someone with very little debt and plenty of short-term liquidity, but whose paycheck still doesn’t cover monthly spending. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 7.09% | <60% safe | ✅Safe | | Current Ratio | 16.21 | >1.5 healthy | ✅Safe | | Cash Flow | -$0.02/share | >0 | 🚨Negative | What you might care about is this: balance-sheet stress does **not** seem to be the main immediate problem. The problem is operating performance. A company can survive a while with low debt and high liquidity, but if losses keep running this deep, that cushion can disappear over time. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $1.72 - 52-Week High: $128.25 - Current: $3.20, Near the low | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(1.15% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PE [Data unavailable] | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > In other words, the market is not paying up for current earnings power—because there isn’t any. The valuation is mostly a bet that the company can stabilize operations, stay compliant on Nasdaq, and turn strategic announcements into real revenue or financing support. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-03-12 | Regained compliance with Nasdaq minimum bid price requirement | Positive — removes one immediate listing overhang, though it came after stress | | 2026-03-10 | Strategic collaboration with UAE-based Citadel Investment | Neutral/Positive — sounds promising, but still needs execution and monetization | | 2026-02-06 | Announced 1-for-50 reverse stock split | Negative — usually a sign the company needed technical action to maintain listing | | 2026-02-05 | Received Nasdaq delisting notice | Negative — confirms recent exchange-compliance pressure | | 2026-01-29 | Received notice on minimum bid price requirement | Negative — early warning that the stock had fallen into trouble territory | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 52.68% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -182.59% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -15.01% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | Mixed | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2024-12-31 | [Data unavailable] | -$0.20 | [Data unavailable] | | 2023-09-30 | [Data unavailable] | $0.00 | [Data unavailable] | **Earnings Trend Interpretation:** There isn’t enough estimate data here to judge beat-or-miss consistency. But the big picture is still clear: earnings are weak, visibility is low, and this is not the kind of company where the market is anchored by dependable quarterly execution. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 0 firms | 0% | | Hold | 0 firms | 0% | | Sell | 0 firms | 0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** [Data unavailable] > For a stock this small, the lack of analyst coverage is not surprising. It usually means less institutional attention, less external validation, and often more volatility. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Profitability Risk:** Net margin of -182.59% and operating margin of -189.02% show the business is deeply loss-making → If this continues, it could lead to further capital raising or dilution. 2. **Listing/Market Structure Risk:** The company recently faced Nasdaq compliance and delisting pressure and used a reverse split to respond → If the stock weakens again, listing concerns could return. 3. **Execution Risk:** Recent strategic collaboration headlines may lift sentiment, but there is no proof yet of material revenue impact → If these initiatives don’t convert into real business, the stock’s speculative premium could fade quickly. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Agape ATP is a very small, high-volatility healthcare-related company that currently trades more on corporate survival and strategic headlines than on proven fundamentals. > > **Key strength:** Its balance sheet looks relatively light on debt and liquid in the short term, so the company is not obviously choking on leverage. > > **Key risk:** The real problem is that the underlying business is still deeply unprofitable, and the recent Nasdaq compliance drama shows how little room for error it has. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis